Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
C.D. PHARMA from Nivelles, company number BE0461479280, closed financial year 2025 with a result of € -10,408 after tax. For that financial year C.D. PHARMA recorded a gross margin of € -1,539 and equity of € 25,306. Compared with financial year 2024, the result moved from € -10,158 to € -10,408. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on May 12, 2026.
€ 25,306
▼ 29% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -10,408
▼ 2 % more loss than in 2024
Profit after tax over the fiscal year.
Loss, nothing to pay out
Reserves fell to € 19,101.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -1,315 | € -1,428 | € -1,358 | € -1,539 | ▼ € 181 |
| Profit after taxes | € -9,638 | € -10,119 | € -10,158 | € -10,408 | ▼ € 250 |
| Equity | € 55,991 | € 45,872 | € 35,714 | € 25,306 | ▼ 29% |
| Total debts | € 233,349 | € 237,085 | € 241,327 | € 245,323 | ▲ 2% |
| Land & buildings | € 104,272 | € 97,891 | € 91,510 | € 85,130 | ▼ 7% |
| Retained profit | € 49,786 | € 39,667 | € 29,509 | € 19,101 | ▼ 35% |
| Balance sheet total | € 289,340 | € 282,957 | € 277,041 | € 270,629 | ▼ 2% |
Key figures of C.D. PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 June 2027.
What happened to C.D. PHARMA?
What happened at C.D. PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 10,408. Source: NBB ↗
- New establishment in Nivelles. KBO
- Start of the company according to the CBE. KBO
In short
From € 9,638 loss in 2022 to € 10,408 loss in 2025.
Management
Behind C.D. PHARMA is PHILIPPE DENIS. It owns 99.5% of EXO PHARMA itself.
Directors
According to the 2025 annual accounts
PHILIPPE DENIS
Director
Establishments
Establishment units
Physical locations of this company
Allée de la Tour-Renard 15
1400 Nivelles
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0461.479.280
- VAT number
- BE 0461.479.280
- Registered office
- Allée de la Tour-Renard 15, 1400 Nivelles
- Names & denominations
- C.D. PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 September 1997
- Peppol
- Not registered